Mexicor, 50 mg/ml 2 ml 10 pcs

Mexicor® reduces manifestations of oxidative stress by inhibiting free-radical lipid peroxidation and increasing the activity of antioxidant enzyme system. It improves cellular energy exchange by activating the energy-synthesizing functions of mitochondria, increasing compensatory activation of aerobic glycolysis, and reducing the degree of inhibition of oxidative processes in the Krebs cycle. The energy-synthesizing effect of the drug is associated with increased delivery and consumption of succinate by cells, realization of the phenomenon of rapid oxidation of succinate acid by succinate dehydrogenase, as well as with activation of the mitochondrial respiratory chain. Upon dissociation of Mexicor® in the cell into succinate and 3-oxypyridine derivative (base), the base exhibits antioxidant effect that stabilizes cell membranes and restores functional activity of cells.

The action of the drug is based on its antioxidant activity, the ability to inhibit free-radical processes (whose pronounced intensification is observed during ischemia and myocardial necrosis, especially during reperfusion) and reduces the damaging effects of free radicals on cardiomyocytes.

It decreases cell membrane viscosity and increases its fluidity and modulates membrane-bound enzymes (calcium-independent FDE, adenylate cyclase, acetylcholinesterase), ion channels and receptor complexes, which help to maintain the structural and functional integrity of biomembranes and improve neurotransport and synaptic transmission. It improves metabolism and blood supply of the brain, microcirculation and rheological properties of blood, reduces platelet aggregation.

It improves functional state of ischemic myocardium, cardiac contractile function, and reduces manifestations of systolic and diastolic dysfunction of the left ventricle. In conditions of coronary insufficiency it increases collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps to preserve the integrity of cardiomyocytes and maintain their functional activity. Effectively restores myocardial contractility in reversible cardiac dysfunction, which is a significant reserve for increasing the contractility of the heart in patients with CHD complicated by heart failure.

In patients with stable angina pectoris the drug increases exercise tolerance and antianginal activity of nitro medicines and improves rheological properties of blood. Adding Mexicor® to standard therapy of CHD improves clinical condition of patients, increases exercise tolerance and improves quality of life.

Mexicor® stabilizes membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculatory disorders at early stages of atherogenesis, has hypolipidemic effect, decreases total cholesterol and low-density lipoproteins (LDL).

Mexicor® causes neuroprotective action on the functional activity and metabolism of ischemic brain, increases resistance of cerebral blood circulation in hypoperfusion, prevents decrease of cerebral blood flow in reperfusion period after ischemia. The drug promotes adaptation to the damaging effects of ischemia by inhibiting the depletion of carbohydrate stores, blocking the post-ischemic fall in glucose and oxygen utilization by the brain and preventing the progressive accumulation of lactate. At the same time, indicators of autoregulatory responses of cerebral vessels are improved.

Mexicor® has nootropic properties, prevents and reduces learning and memory disorders of acute and chronic cerebral vascular diseases, mild and moderate cognitive disorders of different genesis, has an antioxidant effect, increases concentration and performance.

Inclusion of Mexicor® in treatment of patients with acute stroke reduces clinical manifestations of stroke and improves rehabilitation period.

Mexicor® has a selective, not accompanied by sedation and muscle relaxation, anxiolytic action, eliminates anxiety, fear, tension and restlessness and improves adaptation and emotional status.

Indications

Active ingredient

Composition

Active ingredient:

Ethylmethylhydroxypyridine succinate 50 mg;

Auxiliary substances:

succinic acid;

dinatrium edetate;

water for injection;

How to take, the dosage

V/m or intravenously (by stream or dropwise).

In treatment of acute myocardial infarction the drug is administered by IV or IV/m over 14 days, against the background of conventional therapy of myocardial infarction, including nitrates, β-adrenoblockers, ACE inhibitors, thrombolytics, anticoagulant and antiplatelet agents, as well as symptomatic agents, as indicated.

In the first 5 days, for maximum effect, the drug should preferably be administered by IV, in the next 9 days – by IM.

In/v infusion of the drug is carried out by drop infusion, slowly (in order to avoid side effects), on physiological solution or 5% dextrose (glucose) solution in the volume of 100-150 ml for 30-90 minutes. If necessary, a slow trickle administration of the drug, lasting at least 5 minutes, is possible.

The drug is administered (intravenously or intramuscularly) 3 times a day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg/day, single dose – 2-3 mg/kg. The maximum daily dose should not exceed 800 mg, the single dose is 250 mg.

In case of acute stroke, Mexicor® is used as part of treatment in the first 2-4 days v/v, dropwise 200-300 mg 2-3 times daily, after that – v/m 100 mg 3 times daily. The treatment duration is 10-14 days. Later the drug is prescribed in capsules in 100 mg 2 times a day for 14 days and 100 mg 3 times a day for the next 7 days. The frequency and duration of repeated courses of therapy is determined by the physician.

In patients with dyscirculatory encephalopathy in decompensation phase, Mexicor® should be administered by injection or drop infusion in dose of 100 mg 2-3 times daily during 14 days. Then the drug is administered by injection/m 100 mg per day during next 2 weeks. Later the drug is prescribed in capsules 100 mg 2-4 times a day (according to the doctor’s recommendation); the frequency and duration of therapy shall be determined by the doctor.

For the course of prophylaxis of discirculatory encephalopathy the drug is administered in a dosage of 100 mg 2 times a day for 10-14 days.

For treatment of mild and moderate cognitive disorders Mexicor® is administered in a daily dosage of 100-300 mg in mM for 14 days. If necessary, the drug is prescribed in capsules 100 mg 2-4 times a day (as recommended by the physician); the frequency and duration of therapy shall be determined by the physician.

Special Instructions

When treating, caution should be exercised when driving motor vehicles and engaging in other potentially dangerous activities that require increased concentration and quick psychomotor reactions.

Contraindications

Overdose

Symptoms: sleep disturbance (insomnia), in rare cases – slight and transient (up to 1.5-2 hours) increase in BP.

Treatment: the development of overdose symptoms usually does not require the use of curing agents, the above symptoms of sleep disturbances disappear on their own within 24 hours.

In particularly severe cases, the use of one of the oral hypnotics and anxiolytics (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg) is recommended. In case of excessive rise in blood pressure – prescription of hypotensive drugs (under control of blood pressure).

Similarities